Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04088500 | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced… | Phase 2 | terminated | Sep 12, 2019 | Bristol-Myers Squibb | Slow accrual | Enrollment / accrual |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | May 1, 2019 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or…(PALS) | N/A | terminated | May 27, 2015 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | Oct 4, 2016 | X4 Pharmaceuticals | Due to low enrollment, the study was terminated early. | Enrollment / accrual |
| NCT04147143 | CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following… | — | terminated | Oct 31, 2019 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Due to insufficient recruitment rate, recruitmend has been terminated after inclusion of 56 patients | Enrollment / accrual |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
| NCT05052372 | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving… | — | terminated | Sep 22, 2021 | xCures | Sponsor request to terminate study due to enrollment numbers | Enrollment / accrual |
| NCT03387514 | Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis…(UW17104) | Phase 2 | terminated | Jan 2, 2018 | University of Wisconsin, Madison | Termination of funding due to low subject enrollment due to change in standard of care systemic… | Enrollment / accrual |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based… | Phase 1 / Phase 2 | terminated | Apr 20, 2021 | Xennials Therapeutics Australia Pty Ltd | Study was terminated by IP Holder (collaborator), PinotBio Inc. | Other (stated, no rule matched) |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With… | Phase 2 | terminated | Nov 30, 2016 | Marker Therapeutics, Inc. | Futility analysis did not support continuation of the trial | Efficacy / futility |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | — | withdrawn | Sep 30, 2021 | Indiana University | PI decision to cancel research | Other (stated, no rule matched) |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT04928820 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer… | Phase 2 | terminated | Jun 16, 2021 | Jonsson Comprehensive Cancer Center | slow recruitment | Enrollment / accrual |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT00520533 | Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced… | Phase 1 | terminated | Aug 24, 2007 | Ludwig Institute for Cancer Research | Closed prematurely due to toxicity | Safety / toxicity |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon…(ESCALATE) | Phase 3 | terminated | Jan 23, 2020 | MANA RBM | The study was stopped due to insurmountable enrollment challenges affecting trial accrual,… | Enrollment / accrual |
| NCT01727336 | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | Phase 2 | terminated | Nov 16, 2012 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | The study was terminated by the sponsor following unblinding of the Progression Free Survival… | Other (stated, no rule matched) |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant… | Phase 1 / Phase 2 | withdrawn | Oct 17, 2018 | Roswell Park Cancer Institute | lack of funding | Funding |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | Phase 1 | terminated | Aug 3, 2010 | Roswell Park Cancer Institute | no value in finding efficacy | Efficacy / futility |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in… | Phase 1 | terminated | Feb 21, 2020 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | Early Phase 1 | withdrawn | May 27, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23,… | Phase 1 | terminated | Sep 24, 2020 | Shanghai East Hospital | Both the sponsors and collaborator are considering terminating the study. | Other (stated, no rule matched) |
| NCT01582009 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal… | Phase 1 / Phase 2 | terminated | Apr 20, 2012 | Roswell Park Cancer Institute | pts off study, PI left institute | Investigator |
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | withdrawn | Jan 17, 2013 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | Phase 1 | withdrawn | Jul 22, 2021 | Guru P. Sonpavde | Low Accrual | Enrollment / accrual |
| NCT02781506 | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell… | Phase 2 | terminated | May 24, 2016 | University of Texas Southwestern Medical Center | Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming… | Other (stated, no rule matched) |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | Phase 2 | withdrawn | Mar 2, 2022 | University of Oklahoma | PI left University | Investigator |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial… | Phase 2 | terminated | Sep 15, 2016 | H. Lee Moffitt Cancer Center and Research Institute | Study closed early due to futility | Efficacy / futility |
| NCT02419846 | Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly… | N/A | terminated | Apr 17, 2015 | Case Comprehensive Cancer Center | Unable to recruit due to COVID limitations / Funding Unavailable | COVID-19 / pandemic |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With… | Phase 2 | terminated | May 22, 2018 | National Cancer Institute (NCI) | Study was closed for toxicity. | Safety / toxicity |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With… | Phase 1 | terminated | Nov 18, 2020 | Dizal Pharmaceuticals | Due to reasons of internal business strategy, not related to study or site conduct. | Sponsor / business decision |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab,… | Phase 2 | terminated | Feb 10, 2017 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | Phase 2 | terminated | Jul 19, 2016 | University of Alabama at Birmingham | Poor accrual | Enrollment / accrual |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing… | Early Phase 1 | terminated | Dec 26, 2017 | National Cancer Institute (NCI) | it was decided that due to lack of accrual on the trial, and low potential for accruing over the… | Enrollment / accrual |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer… | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by IRB on 3/28/22 | Other (stated, no rule matched) |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian,…(ORION-01) | Phase 1 / Phase 2 | terminated | Apr 4, 2017 | National Cancer Centre, Singapore | The study had poor efficacy. | Efficacy / futility |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian… | Phase 2 | terminated | Sep 14, 2016 | Translational Research in Oncology | not stated | Not stated |
| NCT04961320 | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell… | N/A | withdrawn | Jul 14, 2021 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04150562 | Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | Phase 2 | terminated | Nov 4, 2019 | National Cancer Institute (NCI) | This study was terminated early due to manufacturer withdrawal of support (study medication) due to… | Drug supply |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | N/A | withdrawn | Feb 15, 2019 | Case Comprehensive Cancer Center | Revision to improve cell recovery | Other (stated, no rule matched) |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and…(RENACOL) | Phase 1 / Phase 2 | withdrawn | Nov 3, 2021 | Faron Pharmaceuticals Ltd | Since no patients have been enrolled in RENACOL, and safety and tolerability data is rapidly… | Safety / toxicity |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Apollomics (Australia) Pty. Ltd. | Study terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | Phase 2 | withdrawn | Apr 2, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | accrual on hold | Enrollment / accrual |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma…(RESECT) | Early Phase 1 | terminated | Aug 30, 2017 | University Health Network, Toronto | Difficulties with accrual | Enrollment / accrual |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | Phase 2 / Phase 3 | withdrawn | Mar 12, 2021 | Menoufia University | Poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 10, 2023source: clinicaltrials